Jincheng Pharmaceutical (300233.SZ): Clinical trial of injectable minocycline hydrochloride drug approved

Zhitongcaijing · 3d ago

Zhitong Finance App News, Jincheng Pharmaceutical (300233.SZ) announced that Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., its holding subsidiary, recently received the “Drug Clinical Trial Approval Notice” for injectable minocycline hydrochloride issued by the State Drug Administration.

According to reports, intravenous minocycline hydrochloride injection is suitable for the treatment of infections caused by sensitive isolates of designated bacteria: Rocky Mountain spotted fever, typhus and typhus group, Q fever, rickettsial pox, and tick fever; respiratory infections caused by Mycoplasma pneumoniae; venereal lymphogranuloma caused by Chlamydia trachomatis; parrot fever (bird disease) caused by Chlamydia parrotum; adult non-gonococcal urethritis caused by ureaplasma or chlamydia trachomatis cervical or rectal infections; reflux fever due to reflux; plague caused by Yersinia pestis; by Tulafu Tularemia caused by Lancis bacteria; Cholera caused by Vibrio cholerae; Campylobacter fetalis infection caused by Campylobacter fetalis; Brucellosis due to Brucella (in combination with streptomycin); Baltoniasis caused by Bacillus bacillus bacillus; Granulomatous granuloma caused by Klebsiella granuloma.